<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00112736</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02921</org_study_id>
    <secondary_id>NCI-2012-02921</secondary_id>
    <secondary_id>CDR0000429553</secondary_id>
    <secondary_id>NABTC04-02</secondary_id>
    <secondary_id>NABTC-04-02</secondary_id>
    <secondary_id>U01CA062399</secondary_id>
    <nct_id>NCT00112736</nct_id>
    <nct_alias>NCT00267878</nct_alias>
  </id_info>
  <brief_title>Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma</brief_title>
  <official_title>Phase I/II Study of OSI-774 (Erlotinib) and CCI-779 (Temsirolimus) in Patients With Recurrent Malignant Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Erlotinib and temsirolimus and may stop the growth of tumor cells by blocking some of the
      enzymes needed for cell growth. This phase I/II trial is studying the side effects and best
      dose of temsirolimus when given together with erlotinib and to see how well they work in
      treating patients with recurrent malignant glioma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To define the maximum tolerated dose (MTD) of OSI-774 (erlotinib; Tarceva) in combination
      with CCI-779 (temsirolimus) in patients with recurrent malignant glioma who are not taking
      enzyme-inducing anti-epileptic drugs (EIAEDs). (Phase I) II. To characterize the safety
      profile of OSI-774 (erlotinib) and CCI-779 (temsirolimus). (Phase I) III. To characterize the
      pharmacokinetics of OSI-774 (erlotinib) and CCI-779 (temsirolimus). (Phase I) IV. To
      determine the efficacy of OSI-774 (erlotinib) and CCI-779 (temsirolimus) in patients with
      recurrent malignant glioma as measured by 6-month progression-free survival. (Phase II)

      SECONDARY OBJECTIVES:

      I. Overall progression-free survival. (Phase II) II. Response. (Phase II)

      TERTIARY OBJECTIVES:

      I. To explore the association of response to treatment to the molecular phenotype of the
      tumor. (Phase II) II. Determine whether OSI-774 (erlotinib) and CCI-779 (temsirolimus)
      inhibits EGFR and mTOR and the PI3K-AKT-mTOR and RAS-ERK signaling pathways in tumor
      specimens taken from malignant glioma patients undergoing surgery. (Phase II) III. Tumor
      concentration of OSI-774 (erlotinib) and CCI-779 (temsirolimus). (Phase II)

      OUTLINE: This is a multicenter, phase I, dose-escalation study of temsirolimus followed by a
      phase II study. Patients are stratified according to study phase (I vs II), histology at
      study enrollment (glioblastoma multiforme or gliosarcoma vs anaplastic glioma), preoperative
      candidacy (yes vs no), and presence of measurable or evaluable disease (yes vs no).

      PHASE I: Patients receive oral erlotinib once daily on days 1-28 and temsirolimus IV over 30
      minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease
      progression or unacceptable toxicity.

      Cohorts of 3-6 patients receive escalating doses of temsirolimus until the maximum tolerated
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2
      of 6 patients experience dose-limiting toxicity.

      PHASE II: Patients receive temsirolimus at the MTD and erlotinib as in phase I.

      PHASE II (preoperative component): Patients who are surgical candidates may opt to undergo
      surgical resection of the tumor. Beginning 5-7 days before surgery, these patients receive
      oral erlotinib once daily until surgery. Patients also receive temsirolimus IV over 30
      minutes at the MTD and then undergo surgical resection of the tumor 3-24 hours later.
      Beginning 2-4 weeks after surgery, patients receive temsirolimus at the MTD and erlotinib as
      in phase I.

      PROJECTED ACCRUAL: A total of 3-24 patients will be accrued for the phase I portion of the
      study within 1-8 months. A total of 50 patients (32 patients with glioblastoma multiforme and
      18 with anaplastic glioma) will be accrued for the phase II portion of the study within 8-12
      months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (Phase I)</measure>
    <time_frame>based on first 4 weeks of treatment - cycle 1</time_frame>
    <description>Oral erlotinab at 150mg constant dose, 3 pts will be treated with temsirolimus IV with escalating doses, starting at 50mg. Doses will increase or decrease based on toxicity observed.
3 pts will be treated at each dose level - 3 dose levels were observed: 50mg, 25mg, and 15mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety/Dose Limiting Toxities Phase I</measure>
    <time_frame>first 4 weeks of treatment</time_frame>
    <description>Dose limiting toxities defined as: grade 3 thrombocytopenia, grade 4 anemia and neutropenia, grade &gt;/= nonhematologic toxicity, and failure to recover from toxicites to be eligible for retreatment in 2 weeks of the last dose of either drug. Also grade 3 nonhematologic toxicities only if they wre refractory to maxiaml medical therapy.
MTD defined as dose at which fewer than one-third of patients experienced a DLT
Outcome measure defines number of participants who had a defined dose limiting toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy - Response Phase 1</measure>
    <time_frame>at least 8 weeks of treatment</time_frame>
    <description>pt must have at least 8 weeks of treatment to receive MRI scan, scans are every other cycle (every 2 months). Response measured by a bidimensionally measured leison and clearly defined margins by CT or MRI scan.
Complete Response (CR): complete disappearance of all measurable and evaluable disease. No new lesions, not on any steroids Partial Response (PR): &gt;= 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable disease. No new lesions. Steriod dose must be no greater than max used in 1st 8wks of therapy Stable: not qualify for CR, PR, or progression. Steriod dose must be no greater than max used in 1st 8wks of therapy Progression (PD): 25% increase in the sum of products of all measurable lesions over smallest sum observed, OR clear worsening or failure to return for evalution due to death or deteriorating condition (unless clearly unrelated to brain cancer).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (Phase I)</measure>
    <time_frame>Days 1, 2 of cycle 1, prior to dosing of both drugs, at end of temsirolimus infusion and at 1,2,4,6, and 24 hr after erlotinib administration</time_frame>
    <description>Tersirolimus Cmax (ng/mL) for cycle 1 is presented in the outcome measure table below for the 3 dose levels
blood samples (5ml) was collected in EDTA containing tubes on days 1 and 2 of cycle 1
Collection time points: prior to dosing of both drugs, at end of temsirolimus infusion and at 1,2,4,6, and 24 hr after erlotinib administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free Survival at 6 Months (Phase II)</measure>
    <time_frame>Evaluated at baseline and every other cycle, till Month 6</time_frame>
    <description>Progression (PD): 25% increase in the sum of products of all measurable lesions over smallest sum observed, OR clear worsening or failure to return for evalution due to death or deteriorating condition (unless clearly unrelated to brain cancer).
Responses had to be present on 2 consecutive scans and were centrally reviewed.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Adult Anaplastic Astrocytoma</condition>
  <condition>Adult Anaplastic Oligodendroglioma</condition>
  <condition>Adult Diffuse Astrocytoma</condition>
  <condition>Adult Giant Cell Glioblastoma</condition>
  <condition>Adult Glioblastoma</condition>
  <condition>Adult Gliosarcoma</condition>
  <condition>Adult Mixed Glioma</condition>
  <condition>Adult Pilocytic Astrocytoma</condition>
  <condition>Adult Pineal Gland Astrocytoma</condition>
  <condition>Adult Subependymal Giant Cell Astrocytoma</condition>
  <condition>Recurrent Adult Brain Tumor</condition>
  <arm_group>
    <arm_group_label>Phase 1 (erlotinib &amp; temsirolimus)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PHASE I: Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 (dose escalation). Every 28 days until disease progression or unacceptable toxicity.
pharmacological study: Correlative studies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 temsirolimus MTD &amp; erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 at MTD phse I. Every 28 days until disease progression or unacceptable toxicity.
PHASE II (preoperative component): Patients who are surgical candidates may opt to undergo surgical resection of the tumor. Beginning 5-7 days before surgery, these patients receive oral erlotinib once daily until surgery. Patients also receive temsirolimus IV over 30 minutes at the MTD and then undergo surgical resection of the tumor 3-24 hours later. Beginning 2-4 weeks after surgery, patients receive temsirolimus at the MTD and erlotinib as in phase I.
therapeutic conventional surgery: Undergo surgical resection
laboratory biomarker analysis: Correlative studies</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Phase 1 (erlotinib &amp; temsirolimus)</arm_group_label>
    <arm_group_label>Phase 2 temsirolimus MTD &amp; erlotinib</arm_group_label>
    <other_name>CP-358,774</other_name>
    <other_name>erlotinib hydrochloride</other_name>
    <other_name>OSI-774</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temsirolimus</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Phase 1 (erlotinib &amp; temsirolimus)</arm_group_label>
    <arm_group_label>Phase 2 temsirolimus MTD &amp; erlotinib</arm_group_label>
    <other_name>CCI-779</other_name>
    <other_name>cell cycle inhibitor 779</other_name>
    <other_name>Torisel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Undergo surgical resection</description>
    <arm_group_label>Phase 2 temsirolimus MTD &amp; erlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Phase 2 temsirolimus MTD &amp; erlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Phase 1 (erlotinib &amp; temsirolimus)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically proven intracranial glioblastoma multiforme (GBM) or
             gliosarcoma (GS), anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO),
             anaplastic mixed oligoastrocytoma (AMO), or malignant astrocytoma not otherwise
             specified (NOS) will be eligible for this protocol; patients will be eligible if the
             original histology was low-grade glioma and a subsequent histological diagnosis of a
             malignant glioma is made

          -  All patients must sign an informed consent indicating that they are aware of the
             investigational nature of this study; patients must have signed an authorization for
             the release of their protected health information; patients must be registered in the
             Adult Brain Tumor Consortium (ABTC) Central Office database prior to treatment with
             study drug

          -  Patients must have a life expectancy &gt; 8 weeks

          -  Patients must have a Karnofsky performance status of &gt;= 60

          -  Patients must have recovered from the toxic effects of prior therapy: 4 weeks (28
             days) from any investigational agent, 4 weeks (28 days) from prior cytotoxic therapy,
             two weeks (14 days) from vincristine, 6 weeks (42 days) from nitrosoureas, 3 weeks (21
             days) from procarbazine administration, and 1 week (7 days) for non-cytotoxic agents,
             e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, etc. (radiosensitizer
             does not count); any questions related to the definition of non-cytotoxic agents
             should be directed to the study chair

          -  WBC &gt;= 2,000/ul

          -  ANC &gt;= 1,500/mm^3

          -  Platelet count of &gt;= 100,000/mm^3

          -  Hemoglobin &gt;= 10 gm/dl

          -  Total bilirubin within normal institutional limits

          -  AST (SGOT)/ALT (SGPT) =&lt; 2.5 X institutional ULN

          -  Creatinine &lt; 1.5 mg/dL

          -  Patients must have cholesterol level =&lt; 350 mg/dl and triglycerides level =&lt; 400 mg/dl

          -  Patients must have shown unequivocal evidence for tumor progression by MRI or CT scan;
             a scan should be performed within 14 days prior to registration; the same type of
             scan, i.e., MRI or CT must be used throughout the period of protocol treatment for
             tumor measurement

          -  Patients must have failed prior radiation therapy and must have an interval of greater
             than or equal to 6 weeks (42 days) from the completion of radiation therapy to study
             entry

          -  Patients with prior therapy that included interstitial brachytherapy or stereotactic
             radiosurgery must have confirmation of true progressive disease rather than radiation
             necrosis based upon either PET or Thallium scanning, MR spectroscopy or surgical
             documentation of disease

          -  Patients having undergone recent resection of recurrent or progressive tumor will be
             eligible as long as all of the following conditions apply:

               -  They have recovered from the effects of surgery

               -  Residual disease following resection of recurrent tumor is not mandated for
                  eligibility into the study; to best assess the extent of residual disease
                  post-operatively, a CT/ MRI should be done no later than 96 hours in the
                  immediate post-operative period or at least 4 weeks post-operatively, within 14
                  days prior to registration; if the 96-hour scan is more than 14 days before
                  registration, the scan needs to be repeated; if the steroid dose is increased
                  between the date of imaging and registration, a new baseline MRI/CT is required
                  on a stable or decreasing steroid dosage for at least 5 days

          -  PHASE I: Patients may have had treatment for any number of prior relapses; relapse is
             defined as progression following initial therapy (i.e. radiation+/- chemo if that was
             used as initial therapy)

          -  PHASE I: For the baseline MRI or CT scan prior to registration, patients in the Phase
             I component should be on a steroid dose that has been stable for at least 5 days prior
             to the scan; if the steroid dose is increased between the date of imaging and
             registration a new baseline MR/CT is required

          -  PHASE II: Patients may have had treatment for no more than 2 prior relapses; relapse
             is defined as progression following initial therapy (i.e. radiation+/- chemo if that
             was used as initial therapy); the intent therefore is that patients had no more than 3
             prior therapies (initial and treatment for 2 relapses); if the patient had a surgical
             resection for relapsed disease and no anti-cancer therapy was instituted for up to 12
             weeks, and the patient undergoes another surgical resection, this is considered as 1
             relapse; for patients who had prior therapy for a low-grade glioma, the surgical
             diagnosis of a high-grade glioma will be considered the first relapse

          -  PHASE II: Unstained slides or tissue blocks must be available from at least one prior
             surgery; if available, frozen tissue is also requested from earlier surgeries

          -  PHASE II: Patients who are eligible for participation in the phase II component of the
             study may be enrolled in a pre-operative study to evaluate biological and/or tissue
             correlates

          -  PHASE II: For the baseline MRI or CT scan prior to registration, patients in the phase
             II component who are not participating in the pre-operative component of the study
             should be on a steroid dose that has been stable for at least 5 days prior to the
             scan; if the steroid dose is increased between the date of imaging and registration a
             new baseline MR/CT is required

          -  PHASE II: For the patients in the preoperative component, only a scan showing
             progression is required; for this scan only stable steroids are not required;
             following surgery, a scan should be done no later than 96 hours or at least 4 weeks
             from surgery and on a steroid dose that is stable or decreasing; treatment with
             OSI-774 (erlotinib) and CCI-779 (temsirolimus) post-operatively should start no later
             than 14 days after the scan; if the 96-hour scan is more than 14 days before treatment
             is initiated, the scan needs to be repeated on a stable or decreasing steroid dose

        Exclusion Criteria:

          -  Patients must not be on an enzyme-inducing anti-epileptic drug (EIAED); if previously
             on an EIAED, the patient must be off of it for at least two weeks prior to
             registration

          -  Patients must not have any significant medical illnesses that in the investigator's
             opinion cannot be adequately controlled with appropriate therapy or would compromise
             the patient's ability to tolerate this therapy

          -  Patients with a history of any other cancer (except non-melanoma skin cancer or
             carcinoma in-situ of the cervix), unless in complete remission and off of all therapy
             for that disease for a minimum of 3 years are ineligible

          -  Patients must not have active infection or serious intercurrent medical illness

          -  Patients must not be pregnant/breast feeding and must agree to practice adequate
             contraception; women of childbearing potential must have a negative B-HCG pregnancy
             test documented within 7 days prior to registration; patients must not be pregnant;
             should a woman become pregnant or suspect she is pregnant while participating in this
             study, she should inform her treating physician immediately

          -  Patients must not have any disease that will obscure toxicity or dangerously alter
             drug metabolism

          -  Patients must not have received prior therapy with CCI-779 (temsirolimus), OSI-774
             (erlotinib) or other mTOR or epidermal growth factor receptor inhibitors

          -  HIV-positive patients receiving combination anti-retroviral therapy are excluded from
             the study due to possible retro-viral drug interactions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Wen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute Neuro-Oncology Branch</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol. 2014 Apr;16(4):567-78. doi: 10.1093/neuonc/not247. Epub 2014 Jan 26.</citation>
    <PMID>24470557</PMID>
  </results_reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2005</study_first_submitted>
  <study_first_submitted_qc>June 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2005</study_first_posted>
  <results_first_submitted>April 28, 2015</results_first_submitted>
  <results_first_submitted_qc>May 29, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 15, 2015</results_first_posted>
  <last_update_submitted>May 29, 2015</last_update_submitted>
  <last_update_submitted_qc>May 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled between 2005 and 2008. Patients were recruited from outpatient medical clinics and referrals.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase I (Erlotinib &amp; Temsirolimus)</title>
          <description>PHASE I: Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 (dose escalation). Every 28 days until disease progression or unacceptable toxicity.
erlotinib: Given orally
temsirolimus: Given IV
pharmacological study: Correlative studies</description>
        </group>
        <group group_id="P2">
          <title>Phase II (Erlotinib &amp; Temsirolimus)</title>
          <description>Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 at MTD phse I. Every 28 days until disease progression or unacceptable toxicity.
PHASE II (preoperative component): Patients who are surgical candidates may opt to undergo surgical resection of the tumor. Beginning 5-7 days before surgery, these patients receive oral erlotinib once daily until surgery. Patients also receive temsirolimus IV over 30 minutes at the MTD and then undergo surgical resection of the tumor 3-24 hours later. Beginning 2-4 weeks after surgery, patients receive temsirolimus at the MTD and erlotinib as in phase I.
therapeutic conventional surgery: Undergo surgical resection
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21">12 of Phase I pts treated at MTD and hence considered part of the Phase II analysis</participants>
                <participants group_id="P2" count="47">12 additional pts from phase 1 study were used in analysis for Phase 2 as they were treated at MTD</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>1 pt never had had RX due rapid decline</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>pts had to meet eligibility criteria and recieve at least one dose of treatment.
22 eligible pts enrolled in phase 1, but 1 pt declined before starting any treatment and was excluded from analysis - 12 pts were treated at MTD and thus included in the Phase 2 analysis, hence only 9 patients remained for analysis for phase 1</population>
      <group_list>
        <group group_id="B1">
          <title>Phase I n=9</title>
          <description>PHASE I: Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 (dose escalation). Every 28 days until disease progression or unacceptable toxicity.
erlotinib: Given orally
temsirolimus: Given IV</description>
        </group>
        <group group_id="B2">
          <title>Phase II n=16</title>
          <description>Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 at MTD phse I. Every 28 days until disease progression or unacceptable toxicity.
Anaplastic Glioma
erlotinib: Given orally
temsirolimus: Given IV</description>
        </group>
        <group group_id="B3">
          <title>Phase II n=43</title>
          <description>Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 at MTD phse I. Every 28 days until disease progression or unacceptable toxicity.
Glioblastoma
erlotinib: Given orally
temsirolimus: Given IV</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="43"/>
            <count group_id="B4" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="33" upper_limit="74"/>
                    <measurement group_id="B2" value="47" lower_limit="29" upper_limit="72"/>
                    <measurement group_id="B3" value="50" lower_limit="20" upper_limit="69"/>
                    <measurement group_id="B4" value="51" lower_limit="20" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance Scale (KPS)</title>
          <description>The KPS scores range from 0 (lowest score) to 100 (highest score).
The higher the score the better able to carry out daily activities
100-80: able to carry on normal activity and to work; No special care
70-50: Unable to work; able to live at home and care for most personal needs; varying amount of assistance needed
40-10: unable to care for self, requires equivalent of institutional or hospital care; diseases may be progressing rapidly
0: dead</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90" lower_limit="70" upper_limit="100"/>
                    <measurement group_id="B2" value="90" lower_limit="60" upper_limit="100"/>
                    <measurement group_id="B3" value="90" lower_limit="60" upper_limit="100"/>
                    <measurement group_id="B4" value="90" lower_limit="60" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Chemotherapy treatments</title>
          <units>treatments</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="B2" value="1" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="B3" value="1" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="B4" value="1" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histology</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>anaplastic glioma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>glioblastoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (Phase I)</title>
        <description>Oral erlotinab at 150mg constant dose, 3 pts will be treated with temsirolimus IV with escalating doses, starting at 50mg. Doses will increase or decrease based on toxicity observed.
3 pts will be treated at each dose level - 3 dose levels were observed: 50mg, 25mg, and 15mg</description>
        <time_frame>based on first 4 weeks of treatment - cycle 1</time_frame>
        <population>Per protocol -</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I - Dose Escalation</title>
            <description>Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 at (dose escalation or dose de-escalation). Every 28 days until disease progression or unacceptable toxicity.
Dose levels: cohort 1 - 50mg - 3pts cohort 2 - 25mg -6pt cohort 3 - 15mg - 12pts</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (Phase I)</title>
          <description>Oral erlotinab at 150mg constant dose, 3 pts will be treated with temsirolimus IV with escalating doses, starting at 50mg. Doses will increase or decrease based on toxicity observed.
3 pts will be treated at each dose level - 3 dose levels were observed: 50mg, 25mg, and 15mg</description>
          <population>Per protocol -</population>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety/Dose Limiting Toxities Phase I</title>
        <description>Dose limiting toxities defined as: grade 3 thrombocytopenia, grade 4 anemia and neutropenia, grade &gt;/= nonhematologic toxicity, and failure to recover from toxicites to be eligible for retreatment in 2 weeks of the last dose of either drug. Also grade 3 nonhematologic toxicities only if they wre refractory to maxiaml medical therapy.
MTD defined as dose at which fewer than one-third of patients experienced a DLT
Outcome measure defines number of participants who had a defined dose limiting toxicity.</description>
        <time_frame>first 4 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 - 50mg</title>
            <description>Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 (50mg). Every 28 days until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 - 25 mg</title>
            <description>Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 (25mg). Every 28 days until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 - 15mg</title>
            <description>PHASE I: Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 (15mg). Every 28 days until disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety/Dose Limiting Toxities Phase I</title>
          <description>Dose limiting toxities defined as: grade 3 thrombocytopenia, grade 4 anemia and neutropenia, grade &gt;/= nonhematologic toxicity, and failure to recover from toxicites to be eligible for retreatment in 2 weeks of the last dose of either drug. Also grade 3 nonhematologic toxicities only if they wre refractory to maxiaml medical therapy.
MTD defined as dose at which fewer than one-third of patients experienced a DLT
Outcome measure defines number of participants who had a defined dose limiting toxicity.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy - Response Phase 1</title>
        <description>pt must have at least 8 weeks of treatment to receive MRI scan, scans are every other cycle (every 2 months). Response measured by a bidimensionally measured leison and clearly defined margins by CT or MRI scan.
Complete Response (CR): complete disappearance of all measurable and evaluable disease. No new lesions, not on any steroids Partial Response (PR): &gt;= 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable disease. No new lesions. Steriod dose must be no greater than max used in 1st 8wks of therapy Stable: not qualify for CR, PR, or progression. Steriod dose must be no greater than max used in 1st 8wks of therapy Progression (PD): 25% increase in the sum of products of all measurable lesions over smallest sum observed, OR clear worsening or failure to return for evalution due to death or deteriorating condition (unless clearly unrelated to brain cancer).</description>
        <time_frame>at least 8 weeks of treatment</time_frame>
        <population>Response was reviewed only in those patients treated at the MTD (15mg temsirolimus)</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I 15mg Temsirolimus (MTD Dose)</title>
            <description>PHASE I: Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 (15mg). Every 28 days until disease progression or unacceptable toxicity.
erlotinib: Given orally
temsirolimus: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy - Response Phase 1</title>
          <description>pt must have at least 8 weeks of treatment to receive MRI scan, scans are every other cycle (every 2 months). Response measured by a bidimensionally measured leison and clearly defined margins by CT or MRI scan.
Complete Response (CR): complete disappearance of all measurable and evaluable disease. No new lesions, not on any steroids Partial Response (PR): &gt;= 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable disease. No new lesions. Steriod dose must be no greater than max used in 1st 8wks of therapy Stable: not qualify for CR, PR, or progression. Steriod dose must be no greater than max used in 1st 8wks of therapy Progression (PD): 25% increase in the sum of products of all measurable lesions over smallest sum observed, OR clear worsening or failure to return for evalution due to death or deteriorating condition (unless clearly unrelated to brain cancer).</description>
          <population>Response was reviewed only in those patients treated at the MTD (15mg temsirolimus)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics (Phase I)</title>
        <description>Tersirolimus Cmax (ng/mL) for cycle 1 is presented in the outcome measure table below for the 3 dose levels
blood samples (5ml) was collected in EDTA containing tubes on days 1 and 2 of cycle 1
Collection time points: prior to dosing of both drugs, at end of temsirolimus infusion and at 1,2,4,6, and 24 hr after erlotinib administration</description>
        <time_frame>Days 1, 2 of cycle 1, prior to dosing of both drugs, at end of temsirolimus infusion and at 1,2,4,6, and 24 hr after erlotinib administration</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 - 15mg</title>
            <description>PHASE I: Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 (15mg). Every 28 days until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 - 25 mg</title>
            <description>Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 (25mg). Every 28 days until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 - 50mg</title>
            <description>Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 (50mg). Every 28 days until disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (Phase I)</title>
          <description>Tersirolimus Cmax (ng/mL) for cycle 1 is presented in the outcome measure table below for the 3 dose levels
blood samples (5ml) was collected in EDTA containing tubes on days 1 and 2 of cycle 1
Collection time points: prior to dosing of both drugs, at end of temsirolimus infusion and at 1,2,4,6, and 24 hr after erlotinib administration</description>
          <population>per protocol</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="460" spread="219"/>
                    <measurement group_id="O2" value="428" spread="115"/>
                    <measurement group_id="O3" value="451" spread="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival at 6 Months (Phase II)</title>
        <description>Progression (PD): 25% increase in the sum of products of all measurable lesions over smallest sum observed, OR clear worsening or failure to return for evalution due to death or deteriorating condition (unless clearly unrelated to brain cancer).
Responses had to be present on 2 consecutive scans and were centrally reviewed.</description>
        <time_frame>Evaluated at baseline and every other cycle, till Month 6</time_frame>
        <population>Primary endpoint PFS6 date of registration; Sample size chosen to discriminate between 15% &amp; 35% PFS6 rates for GBM patients. With accrual 32 GBM patients, trial would be considered successful if 8 achieved PFS6. This yields 0.92 power to detect a 35% PFS6 rate, with 0.90 probability of rejecting the treatment regimen if the PFS6 rate is only 15%.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase II n=43</title>
            <description>Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 at MTD phse I. Every 28 days until disease progression or unacceptable toxicity.
Glioblastoma
erlotinib: Given orally
temsirolimus: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival at 6 Months (Phase II)</title>
          <description>Progression (PD): 25% increase in the sum of products of all measurable lesions over smallest sum observed, OR clear worsening or failure to return for evalution due to death or deteriorating condition (unless clearly unrelated to brain cancer).
Responses had to be present on 2 consecutive scans and were centrally reviewed.</description>
          <population>Primary endpoint PFS6 date of registration; Sample size chosen to discriminate between 15% &amp; 35% PFS6 rates for GBM patients. With accrual 32 GBM patients, trial would be considered successful if 8 achieved PFS6. This yields 0.92 power to detect a 35% PFS6 rate, with 0.90 probability of rejecting the treatment regimen if the PFS6 rate is only 15%.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected weekly for the first cycle and then at the start of each cycle while on treatment and at time of off study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Phase I (Erlotinib &amp; Temsirolimus)</title>
          <description>PHASE I: Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 (dose escalation). Every 28 days until disease progression or unacceptable toxicity.
erlotinib: Given orally
temsirolimus: Given IV
pharmacological study: Correlative studies</description>
        </group>
        <group group_id="E2">
          <title>Phase II (Erlotinib &amp; Erlotinib)</title>
          <description>Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 at MTD phse I. Every 28 days until disease progression or unacceptable toxicity.
PHASE II (preoperative component): Patients who are surgical candidates may opt to undergo surgical resection of the tumor. Beginning 5-7 days before surgery, these patients receive oral erlotinib once daily until surgery. Patients also receive temsirolimus IV over 30 minutes at the MTD and then undergo surgical resection of the tumor 3-24 hours later. Beginning 2-4 weeks after surgery, patients receive temsirolimus at the MTD and erlotinib as in phase I.
therapeutic conventional surgery: Undergo surgical resection
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <description>Cardiac ischemia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>retinopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>generalized muscle weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <description>normal ANC</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood Cells</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Leukopenia</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Thrombocytopenia</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Liver Function Test abnormality</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>SGOT, SGPT</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decrease</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>lymphopenia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>hypercholesterolemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>hypertriglyceridemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>hypophosphatemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>hypernatremia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <description>Pain in Limb</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Patrick Y Wen</name_or_title>
      <organization>Adult Brain Tumor Consortium (ABTC)</organization>
      <email>pwen@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

